The Ohio State University Comprehensive Cancer Center (OSUCCC) Pharmacoanalytical Shared Resource (PhASR) has been in development since 2004. PhASR provides bioanalytical method development, quantitative sample analysis, and pharmacokinetic/pharmacodynamic (PK/PD) experimental design and data analysis to support pre-clinical and clinical cancer drug development. PhASR's objectives are to provide: 1) high-quality, state-of-the-art analytical expertise and instrumentation for quantitation of drugs and metabolites in biological specimens at cost-competitive rates;2) PK/PD data for incorporation into clinical decision-making;and 3) expertise in PK/PD study design and data interpretation to support submission of clinical protocols, grants, and publications. PhASR is directed by Dr. Kenneth K. Chan, with additional support from Technical Director, Dr. Mitch A. Phelps. An additional staff of 2.70 full-time employees provides support for sample processing, method development and PK/PD data analysis and modeling. Outstanding institutional support is provided by the OSUCCC and College of Pharmacy's Division of Pharmaceutics that houses the fully-equipped pharmaceutical research laboratories of Drs Chan and Phelps which comprise PhASR. Major equipment in PhASR includes 3 LC-MS systems and 2 stand-alone LC-UV systems ideally suited for drug quantitation and metabolite identification. These systems include a quadrupole-time-of-flight and two triple-quadrupole mass spectrometers, one of which is supported by an ultra-high pressure liquid chromatography system expandable for automated sample processing and high throughput enalysis. Additional LC-MS systems to develop and run biological correlative assays are available. By leveraging outstanding institutional partnerships, PhASR is able to offer its services to OSUCCC members at reduced rates. In the past 12 months PhASR staff has analyzed more than 2,600 samples and has logged nearly 1,700 hours for analytical method development and PK/PD experimental design and data analysis. Neariy 95% of this activity supported 27 members in 5 of the 6 programs within the OSUCCC. Recent highlights of work by PhASR researchers include design of an active flavopiridol dosing schedule and pharmacokinetic modeling of data from 8 clinical trials;development, validation and application of ultrasensitive assays (pM) to support clinical investigations of Bcl-2 and ribonucleotide reductase targeted antisense therapies (G3139 and GTI-2040);validation and application of methods for quantitation of low dose decitabine and resulting intracellular endogenous nucleoside and drug phosphates and global and regional DNA methylation;and pre-clinical pharmacokinetic and metabolism studies of the novel natural product, silvestrol, now in pre-clinical development by the OSUCCC and the NCI. In its short time as a developing resource, PhASR has made these and other significant contributions resulting in high impact publications, grant proposals and funding for OSUCCC investigators. Institutional support and OSUCCC investigators'recognition of the quality of PhASR capabilities and services have insured the continued growth and success of this highly valued shared resource.

Public Health Relevance

Ohio State University Comprehensive Cancer Center (OSUCCC) Pharmacoanalytical Shared Resource (PhASR) provides cost effective, high quality and state-of-the-art bioanalytical method development quantitative sample analysis, and pharmacokinetic/pharmacodynamic experimental design and data analysis to support pre-clinical and clinical cancer drug development

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601827
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$113,739
Indirect Cost
$39,156
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
McKenna, Mary K; Noothi, Sunil K; Alhakeem, Sara S et al. (2018) Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia. Blood 131:2943-2954

Showing the most recent 10 out of 2602 publications